Product Description: DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively)[1].
Applications: Cancer-programmed cell death
Formula: C8H4N4O6
References: [1]Honoré T, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 1988;241(4866):701-703./[2]Lee SH, et al. Selective excitatory actions of DNQX and CNQX in rat thalamic neurons. J Neurophysiol. 2010;103(4):1728-1734./[3]Sharp JW, et al. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995;687(1-2):114-124.
CAS Number: 2379-57-9
Molecular Weight: 252.14
Compound Purity: 99.26
Research Area: Cancer
Solubility: DMSO : ≥ 35 mg/mL/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: iGluR
English
Deutsch
